B Clarkson

4.5k total citations
86 papers, 3.6k citations indexed

About

B Clarkson is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, B Clarkson has authored 86 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 24 papers in Genetics and 18 papers in Molecular Biology. Recurrent topics in B Clarkson's work include Acute Myeloid Leukemia Research (25 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (16 papers). B Clarkson is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (16 papers). B Clarkson collaborates with scholars based in United States, Germany and United Kingdom. B Clarkson's co-authors include Jerrold Fried, A.G. Perez, A Strife, Dorothy Bishop, David Wisniewski, Z Arlin, Toby Gee, Sanford Kempin, C Lambek and Étienne de Harven and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

B Clarkson

84 papers receiving 3.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
B Clarkson 1.3k 1.1k 824 771 696 86 3.6k
M. F. Greaves 1.2k 0.9× 1.5k 1.4× 472 0.6× 582 0.8× 208 0.3× 48 3.8k
Finbarr E. Cotter 848 0.6× 2.6k 2.4× 872 1.1× 1.3k 1.6× 1.2k 1.7× 111 5.0k
Edward D. Ball 1.1k 0.9× 1.2k 1.1× 364 0.4× 1.2k 1.6× 281 0.4× 176 3.5k
Sherif S. Farag 1.8k 1.3× 877 0.8× 594 0.7× 1.3k 1.6× 356 0.5× 137 4.2k
Beverly S. Mitchell 1.0k 0.8× 3.6k 3.3× 715 0.9× 1.2k 1.5× 303 0.4× 125 5.7k
Eric Sariban 1.0k 0.8× 1.1k 1.0× 1.4k 1.7× 518 0.7× 218 0.3× 107 3.5k
John P. McKearn 514 0.4× 1.9k 1.7× 416 0.5× 939 1.2× 416 0.6× 56 3.7k
R. Ford 359 0.3× 1.7k 1.6× 911 1.1× 1.3k 1.7× 1.1k 1.6× 149 4.2k
Robert Sutherland 528 0.4× 982 0.9× 403 0.5× 357 0.5× 223 0.3× 48 2.7k
William H. Fleming 674 0.5× 1.4k 1.3× 649 0.8× 739 1.0× 179 0.3× 107 4.0k

Countries citing papers authored by B Clarkson

Since Specialization
Citations

This map shows the geographic impact of B Clarkson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Clarkson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Clarkson more than expected).

Fields of papers citing papers by B Clarkson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Clarkson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Clarkson. The network helps show where B Clarkson may publish in the future.

Co-authorship network of co-authors of B Clarkson

This figure shows the co-authorship network connecting the top 25 collaborators of B Clarkson. A scholar is included among the top collaborators of B Clarkson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Clarkson. B Clarkson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clarkson, B, et al.. (2003). Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 17(7). 1211–1262. 83 indexed citations
2.
3.
Wisniewski, David, A Strife, & B Clarkson. (1996). c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells.. PubMed. 10(9). 1436–42. 32 indexed citations
4.
Clarkson, B, A Strife, Alexendar R. Perez, C Lambek, & David Wisniewski. (1993). Integration of Molecular and Biological Abnormalities in Quest for Selective Treatment of Chronic Myelogenous Leukemia (CML). Leukemia & lymphoma. 11(sup2). 81–100. 6 indexed citations
5.
Wisniewski, David, A Strife, Alexendar R. Perez, et al.. (1992). Constitutive expression of p53 protein in enriched normal human marrow blast cell populations [see comments]. Blood. 79(8). 1982–1986. 29 indexed citations
6.
Scheinberg, David A., Chaitanya Divgi, Martin C. Graham, et al.. (1991). A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.. Journal of Clinical Oncology. 9(3). 478–490. 188 indexed citations
7.
Schneider, Andrew M., David J. Straus, Alice E. Schluger, et al.. (1990). Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.. Journal of Clinical Oncology. 8(1). 94–102. 44 indexed citations
8.
Straus, David J., Jeffrey J. Gaynor, Jane Myers, et al.. (1990). Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.. Journal of Clinical Oncology. 8(7). 1173–1186. 125 indexed citations
9.
Clarkson, B, Jeffrey J. Gaynor, C. Little, et al.. (1990). Importance of Long-Term Follow-up in Evaluating Treatment Regimens for Adults with Acute Lymphoblastic Leukemia. Hämatologie und Bluttransfusion. 33. 397–408. 20 indexed citations
10.
Straus, David J., Jeffrey J. Gaynor, Jane Myers, et al.. (1989). Results and Prognostic Factors Following Optimal Treatment of Advanced Hodgkin’s Disease. Recent results in cancer research. 117. 191–196. 1 indexed citations
11.
Atzpodien, Jens, Christoph Bührer, Subhash C. Gulati, et al.. (1989). Induction of Nonspecific Cell-Mediated Cytotoxicity: A Multisignal Event and its Cellular Regulation. Hämatologie und Bluttransfusion. 32. 273–280. 1 indexed citations
12.
Tanimoto, Mitsune, et al.. (1989). Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.. PubMed. 3(5). 339–48. 80 indexed citations
13.
Clarkson, B. (1985). Chronic myelogenous leukemia: is aggressive treatment indicated?. Journal of Clinical Oncology. 3(2). 135–139. 19 indexed citations
14.
Hiddemann, Wolfgang, Th. Büchner, M. Andreeff, et al.. (1983). Vergleich der Therapieeffektivitat von zwei Induktionsprotokollen bei akuter myeloischer Leukämie (AML) mittels exakter Quantifizierung der Knochenmarkzellularität. Oncology Research and Treatment. 6(4). 179–183. 2 indexed citations
15.
Straus, David J., et al.. (1981). The treatment of advanced hodgkin's disease. Annals of Hematology. 43(2). 119–124. 3 indexed citations
16.
Fried, Jerrold, A.G. Perez, & B Clarkson. (1980). Quantitative analysis of cell cycle progression of synchronous cells by flow cytometry. Experimental Cell Research. 126(1). 63–74. 14 indexed citations
17.
Garrett, T. J., Toby Gee, Philip Lieberman, Susan McKenzie, & B Clarkson. (1976). The role of bone marrow aspiration and biopsy in detecting marrow involvement by nonhematologic malignancies. Cancer. 38(6). 2401–2403. 13 indexed citations
18.
Yataganas, Xenophon, et al.. (1975). Evaluation of a Feulgen- type reaction in suspension using flow microfluorimetry and a cell separation technique.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 19(1). 71–8. 12 indexed citations
19.
Polliack, Aaron, Nina Lampen, B Clarkson, et al.. (1973). IDENTIFICATION OF HUMAN B AND T LYMPHOCYTES BY SCANNING ELECTRON MICROSCOPY. The Journal of Experimental Medicine. 138(3). 607–624. 256 indexed citations
20.
Cw, Young, et al.. (1960). The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine).. PubMed. 8. 77–83. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. F. Greaves Breakdown of academic impact, for papers by Finbarr E. Cotter Breakdown of academic impact, for papers by Edward D. Ball Breakdown of academic impact, for papers by Sherif S. Farag Breakdown of academic impact, for papers by Beverly S. Mitchell Breakdown of academic impact, for papers by Eric Sariban Breakdown of academic impact, for papers by John P. McKearn Breakdown of academic impact, for papers by R. Ford Breakdown of academic impact, for papers by Robert Sutherland Breakdown of academic impact, for papers by William H. Fleming
Rankless by CCL
2026